Workflow
朗玛信息(300288) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥114,140,717.02, a decrease of 4.38% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was ¥16,933,654.95, down 14.12% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,030,370.37, a decline of 8.06% compared to the previous year[3]. - The company reported a 33.18% decline in net profit attributable to shareholders compared to the previous year, mainly due to decreased revenue from subsidiaries[9]. - The net profit for Q3 2024 was CNY 43,572,464.08, a decrease of 28.3% compared to CNY 60,786,587.32 in Q3 2023[24]. - The operating profit for Q3 2024 was CNY 49,766,611.05, down 39.2% from CNY 81,922,981.00 in the same period last year[24]. - The total comprehensive income for Q3 2024 was CNY 43,572,464.08, down from CNY 60,786,587.32 in Q3 2023, indicating a decline of 28.3%[24]. - The total profit for Q3 2024 was CNY 49,505,322.42, down 30.5% from CNY 71,145,139.74 in Q3 2023[24]. Cash Flow and Assets - The net cash flow from operating activities decreased by 49.96% year-on-year, totaling ¥29,551,522.31[3][10]. - The company's cash and cash equivalents at the end of the reporting period amounted to ¥278,543,918.64, down from ¥302,448,110.89 at the beginning of the period[17]. - Cash flow from operating activities for Q3 2024 was CNY 29,551,522.31, a decline of 50% compared to CNY 59,061,118.56 in Q3 2023[26]. - The cash and cash equivalents at the end of Q3 2024 were CNY 278,513,918.64, a decrease from CNY 375,316,136.66 at the end of Q3 2023[26]. - Total assets at the end of the reporting period were ¥1,894,500,572.14, reflecting a slight increase of 0.65% from the end of the previous year[3]. - Total assets reached CNY 1.89 billion, up from CNY 1.88 billion, indicating a growth of 0.1% year-over-year[20]. - Non-current assets totaled CNY 1.50 billion, an increase of 0.4% from CNY 1.50 billion in Q3 2023[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,551, with the largest shareholder, Wang Wei, holding 32.10% of the shares, amounting to 108,496,015 shares[11]. - The company's equity attributable to shareholders increased by 1.39% to ¥1,633,767,174.05 compared to the end of the previous year[3]. - The company's equity attributable to shareholders increased to CNY 1.63 billion, up from CNY 1.61 billion, reflecting a growth of 1.5%[21]. Operational Metrics - Total operating revenue for Q3 2024 was CNY 298.23 million, a decrease of 14.2% compared to CNY 347.57 million in Q3 2023[22]. - Total operating costs for Q3 2024 were CNY 265.00 million, down 7.5% from CNY 286.97 million in the same period last year[22]. - Research and development expenses for Q3 2024 amounted to CNY 27.76 million, a decrease of 9.5% from CNY 30.72 million in Q3 2023[22]. - The company reported a net profit margin of approximately 10.5% for Q3 2024, compared to 12.5% in Q3 2023[22]. - The basic earnings per share for Q3 2024 was CNY 0.12, compared to CNY 0.18 in Q3 2023, reflecting a 33.3% decrease[24]. Inventory and Receivables - Inventory increased by 36.20% year-on-year, mainly due to higher stock levels at subsidiaries[7]. - Accounts receivable increased to CNY 49.23 million from CNY 38.38 million, reflecting a growth of 28.5% year-over-year[20]. - Inventory rose to CNY 12.32 million, up 36.5% from CNY 9.05 million in the previous year[20]. - Contract assets grew by 39.84% compared to the beginning of the year, primarily due to unbilled revenue from the company's services[8]. Other Income and Expenses - Other income decreased by 72.48% year-on-year, primarily due to a reduction in government subsidies received[9]. - The company incurred financial expenses of CNY -1,963,015.66 in Q3 2024, compared to CNY -2,774,451.05 in Q3 2023[24]. - The company reported a decrease in interest income to CNY 3,491,123.45 in Q3 2024 from CNY 4,969,033.44 in Q3 2023, a drop of 29.8%[24]. Product Development - The company has developed a medical AI product called "39AI General Practitioner," which has been registered and is aimed at medical Q&A, health consultation, and assisting doctors in clinical diagnosis[15]. - As of the end of the third quarter, "39AI General Practitioner" has not generated direct revenue for the company, but ongoing product developments will be disclosed as required[16]. - The company has been recognized as one of the top 100 internet enterprises in China, ranking 64th, and is the only internet medical enterprise on the list[14].